Key Takeaways Gilead shares rose 26.5% YTD, outpacing industry, sector, and S&P 500 benchmarks.FDA cleared HIV prevention drug Yeztugo, the first twice-yearly injectable PrEP.GILD's Trodelvy shows strength, while cell therapy faces competitive challenges.Gilead Sciences, Inc. (GILD) , one of the top biotech companies, has put up a robust performance so far in 2025. Shares of the company have surged 26.5% year to date compared with the industry’s growth of 6%.The stock has also outperformed the sector and th ...